Clinical trial
A Randomized, Double-Blind, Positive-Controlled, Parallel-Group, Multicenter Phase III Clinical Trial to Compare Efficacy and Safety of YK-1169 Versus Ceftazidime-Avibactam for Injection in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
NCT07634198 is registered in ClinicalTrials.gov with Nanjing Yoko Biomedical Co., Ltd. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized, Double-Blind, Positive-Controlled, Parallel-Group, Multicenter Phase III Clinical Trial to Compare Efficacy and Safety of YK-1169 Versus Ceftazidime-Avibactam for Injection in Adults With Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (HABP/VABP)
- Lead sponsor
- Nanjing Yoko Biomedical Co., Ltd.
- Phase
- Phase 3
- Overall status
- Not yet recruiting
- Start date
- June 4, 2026
- Completion date
- April 1, 2028
- Enrollment
- 590 (estimated)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
hospital-acquired bacterial pneumonia (habp), ventilator-associated bacterial pneumonia (vabp)